France at a glance
- Population
- 68.7 million 2025
- Life expectancy at birth
- 83.0 years, 2024
- People aged 65 and over
- 22.5 % of people, 2025
- Health spending per person
- 5,327 US$ per person, 2024
- Doctors
- 3.28 per 1,000 people, 2022
Updated
Reviewed by Vidhi Upadhyay
France Newborn Genome Sequencing Market Industry Trends and Forecast to 2034: Segmented by (Program, Condition, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$39.5 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $9.1 Mn | — | — |
| 2025 (base) | $10.8 Mn | +$1.7 Mn | — |
| 2026 (forecast) | $12.8 Mn | +$2.0 Mn | +18.6% |
| 2027 (forecast) | $15.2 Mn | +$2.4 Mn | +40.7% |
| 2028 (forecast) | $18.1 Mn | +$2.8 Mn | +66.8% |
| 2029 (forecast) | $21.4 Mn | +$3.4 Mn | +97.9% |
| 2030 (forecast) | $25.4 Mn | +$4.0 Mn | +134.7% |
| 2031 (forecast) | $30.1 Mn | +$4.7 Mn | +178.3% |
| 2032 (forecast) | $35.7 Mn | +$5.6 Mn | +230.1% |
| 2033 (forecast) | $42.4 Mn | +$6.6 Mn | +291.5% |
| 2034 (forecast) | $50.3 Mn | +$7.9 Mn | +364.3% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $10.8 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $50.3 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 18.6% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Program, condition and end user (see all) |
| Key players | Illumina, Inc., GeneDx, Natera, Genomics England, Fulgent Genetics (see all) |
| Regulator in France | ANSMSource: ANSM, French medicines agency. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Newborn genome sequencing reads a baby's DNA to find treatable genetic conditions early, beyond standard newborn screening.
Key segments of the newborn Genome Sequencing market include program (Research Programs, National Screening Pilots and Private Testing) and condition (Metabolic, Immune and Neurological).
The falling cost of DNA sequencing, more targeted medicines, large national genome programmes and growing use of genetic results in everyday care are driving the newborn Genome Sequencing market.
Routine use of genomics in screening, pharmacy and primary care gives the newborn Genome Sequencing market large room to grow.
Data privacy concerns, limited reimbursement for some tests, shortages of genetic counsellors and complex data analysis hold back the newborn Genome Sequencing market.
The newborn Genome Sequencing market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by ANSM, the French medicines agency.[1] National health insurance (Assurance Maladie) pays back part of most care costs, and the HAS, the French National Authority for Health, advises on what it should cover.[2]
[1] ANSM, French medicines agency. Checked 14 Nov 2026.
[2] Assurance Maladie (ameli.fr). Checked 14 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for newborn Genome Sequencing. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in France.
What doctors and scientists are doing in Newborn Genome Sequencing right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 16 Nov 2026.
[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 17 Nov 2026.
[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 16 Nov 2026.
From our blog
France · 1 shared keyword
France · 1 shared keyword
France
France
France
France
Digital Health · France
Healthcare Services · France
Healthcare Services · France
Medical Devices · France
Digital Health · France
Medical Devices · France